ReviewFrontiers in medicine2025
Beyond joints: the importance of animal models in exploring rheumatoid arthritis comorbidities.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Nanozymes in Rheumatoid Arthritis Treatment Through Disease Stage-Oriented Strategies.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Joint inflammation is the most prominent feature of rheumatoid arthritis (RA), but this disease can affect practically any organ of the body. The association between RA and comorbidities is multifaceted, involving traditional risk factors, chronic inflammation, and the effects of medications. A large number of animal models have been developed for the study of RA. All of them developed histopathological changes, such as human diseases, and often experienced other comorbidities. The choice of one model or another depends on several factors. It is important to bear in mind, for example, the study of pathophysiological mechanisms, the progression, and the activated autoimmunity, among others. It is also necessary to know what comorbidities are described in each model, as the selection may depend on the possibility of replicating these comorbidities. In this review, we will focus on the study of cardiovascular, musculoskeletal, and hepatic comorbidities in the four most used and induced RA models: collagen-induced arthritis (CIA), adjuvant-induced arthritis (AIA), pristane-induced arthritis (PIA), and serum transfer K/BxN. In this manuscript we offer guidance on how these models replicate RA key comorbidities and how to choose the most suitable RA model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.